{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:02:49Z","timestamp":1773993769540,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40261-022-01124-y","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T17:03:13Z","timestamp":1646154193000},"page":"253-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-3494","authenticated-orcid":false,"given":"Yuki","family":"Takumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Shiroiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kokoro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"1124_CR1","unstructured":"National Cancer Registry in Japan (2016\u20132018). Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/excel\/cancer_incidenceNCR(2016-2018).xlsof subordinate document. Accessed 29 July 2021."},{"key":"1124_CR2","doi-asserted-by":"publisher","unstructured":"Iwata H, Saji S, Ikeda M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast Cancer. 2020;27(1):1\u20133. https:\/\/doi.org\/10.1007\/s12282-019-01021-x(Epub 2019 Nov 22. Erratum in: Breast Cancer. 2021;28(4):987).","DOI":"10.1007\/s12282-019-01021-x"},{"issue":"4","key":"1124_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452\u201378.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9555","key":"1124_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29\u201336.","journal-title":"Lancet"},{"issue":"25","key":"1124_CR5","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","volume":"29","author":"EA Perez","year":"2011","unstructured":"Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366\u201373.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1124_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"key":"1124_CR7","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384.","journal-title":"N Engl J Med"},{"key":"1124_CR8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372.","journal-title":"N Engl J Med"},{"issue":"4","key":"1124_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jval.2018.11.014","volume":"22","author":"LP Garrison Jr","year":"2019","unstructured":"Garrison LP Jr, Babigumira J, Tournier C, et al. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States. Value Health. 2019;22(4):408\u201315.","journal-title":"Value Health."},{"key":"1124_CR10","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"issue":"6","key":"1124_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217778","volume":"14","author":"A Hajjar","year":"2019","unstructured":"Hajjar A, Ergun MA, Alagoz O, Rampurwala M. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. PLoS ONE. 2019;14(6): e0217778.","journal-title":"PLoS ONE"},{"issue":"11","key":"1124_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.27074","volume":"3","author":"N Kunst","year":"2020","unstructured":"Kunst N, Wang SY, Hood A, et al. Cost-effectiveness of neoadjuvant-adjuvant treatment strategies for women with ERBB2 (HER2)-positive breast cancer. JAMA Netw Open. 2020;3(11): e2027074.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1124_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/cncr.22806","volume":"110","author":"LP Garrison Jr","year":"2007","unstructured":"Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007;110(3):489\u201398. https:\/\/doi.org\/10.1002\/cncr.22806 (PMID: 17592827).","journal-title":"Cancer"},{"issue":"3","key":"1124_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/annonc\/mdm488","volume":"19","author":"M Lidgren","year":"2008","unstructured":"Lidgren M, J\u00f6nsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19(3):487\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdm488 (Epub 2007 Dec 6 PMID: 18065409).","journal-title":"Ann Oncol"},{"issue":"6","key":"1124_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.2006.06.4220","volume":"25","author":"NL Liberato","year":"2007","unstructured":"Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625\u201333. https:\/\/doi.org\/10.1200\/JCO.2006.06.4220 (Erratum in: J Clin Oncol. 2007;25(25):4030. PMID: 17308267).","journal-title":"J Clin Oncol"},{"issue":"6","key":"1124_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2006.06.3081","volume":"25","author":"AW Kurian","year":"2007","unstructured":"Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2\/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634\u201341. https:\/\/doi.org\/10.1200\/JCO.2006.06.3081 (PMID: 17308268).","journal-title":"J Clin Oncol"},{"key":"1124_CR17","unstructured":"Macedo A, Monteiro I, Andrade S, Cirrincione A, Ray J. Custo-efectividade de trastuzumab no tratamento de doentes com cancro da mama em est\u00e1dios iniciais em Portugal [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal]. Acta Med Port. 2010;23(3):475\u201382 (Portuguese. Epub 2010 Jun 14. PMID: 20654267)."},{"issue":"1","key":"1124_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40273-017-0557-6","volume":"36","author":"A Ansaripour","year":"2018","unstructured":"Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2018;36(1):91\u2013103. https:\/\/doi.org\/10.1007\/s40273-017-0557-6 (Erratum in: Pharmacoeconomics. 2018 Feb 23. PMID: 28795341; PMCID: PMC5775392).","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1124_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/02841860601096841","volume":"46","author":"J Norum","year":"2007","unstructured":"Norum J, Olsen JA, Wist EA, L\u00f8nning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 2007;46(2):153\u201364. https:\/\/doi.org\/10.1080\/02841860601096841 (PMID: 17453363).","journal-title":"Acta Oncol"},{"key":"1124_CR20","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808\u201315.","journal-title":"J Clin Oncol"},{"key":"1124_CR21","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1002\/cncr.24621","volume":"115","author":"XL Du","year":"2009","unstructured":"Du XL, Xia R, Liu CC, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115:5296\u2013308.","journal-title":"Cancer"},{"key":"1124_CR22","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1200\/JCO.2007.12.0832","volume":"25","author":"DA Patt","year":"2007","unstructured":"Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25:3871\u20136.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1124_CR23","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","volume":"38","author":"M Sawaki","year":"2020","unstructured":"Sawaki M, Taira N, Uemura Y, RESPECT study group, et al. Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J Clin Oncol. 2020;38(32):3743\u201352.","journal-title":"J Clin Oncol"},{"key":"1124_CR24","unstructured":"Woods B, Sideris E, Palmer S, et al. NICE DSU technical support document 19. Partitioned survival analysis for decision modelling in health care: a critical review. NICE Decision Support Unit, 2017. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/06\/Partitioned-Survival-Analysis-final-report.pdf of subordinate document. Accessed 29 July 2021."},{"key":"1124_CR25","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. Official guideline for cost-effectiveness evaluation. Guideline for cost-effectiveness evaluation in Japan (second edition) [English]. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf of subordinate document. Accessed 29 July 2021."},{"issue":"2","key":"1124_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health."},{"key":"1124_CR27","unstructured":"National Institute of Health and Care Excellence Guide to the methods of technology appraisal. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 of subordinate document. Accessed 29 July 2021."},{"key":"1124_CR28","unstructured":"Statistic Japan report in 2018, Table 2-20 Data is available by 5 years of age. http:\/\/www.stat.go.jp\/data\/nihon\/02.html of subordinate document. Accessed 29 July 2021."},{"key":"1124_CR29","unstructured":"Source for natural mortality rates in Japan in 2016\u20132017. https:\/\/www.mhlw.go.jp\/toukei\/list\/81-1.html of subordinate document. Accessed 29 July 2021."},{"key":"1124_CR30","unstructured":"Statistic Japan report in 2018, Table 2-20 Data is available by 5 years of age http:\/\/www.stat.go.jp\/data\/nihon\/02.html. Accessed 29 July 2021."},{"issue":"5","key":"1124_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"key":"1124_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/1-4020-5511-0","volume-title":"EQ-5D value sets: inventory, comparative review and user guide","author":"A Szende","year":"2007","unstructured":"Szende A, Oppe M, Devlin NJ. EQ-5D value sets: inventory, comparative review and user guide. Dordrecht: Springer; 2007."},{"issue":"4","key":"1124_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/hec.673","volume":"11","author":"A Tsuchiya","year":"2002","unstructured":"Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11(4):341\u201353.","journal-title":"Health Econ"},{"issue":"6","key":"1124_CR34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","volume":"95","author":"A Lloyd","year":"2006","unstructured":"Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683\u201390.","journal-title":"Br J Cancer"},{"key":"1124_CR35","doi-asserted-by":"publisher","unstructured":"Direct costs. In: Kirch W, editor. Encyclopedia of public health. Springer, Dordrecht. https:\/\/doi.org\/10.1007\/978-1-4020-5614-7_799.","DOI":"10.1007\/978-1-4020-5614-7_799"},{"issue":"4","key":"1124_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","volume":"6","author":"AH Briggs","year":"1997","unstructured":"Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6(4):327\u201340.","journal-title":"Health Econ"},{"issue":"11","key":"1124_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-7547-11-22","volume":"1","author":"T Shiroiwa","year":"2013","unstructured":"Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc. 2013;1(11):22.","journal-title":"Cost Eff Resour Alloc."},{"key":"1124_CR38","unstructured":"Government Statistical Office (e-Stat), abridged life table in 2019(female). https:\/\/www.e-stat.go.jp of subordinate document. Accessed 29 July 2021 (Japanese)."},{"issue":"3","key":"1124_CR39","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11136-015-1108-2","volume":"25","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016;25(3):707\u201319.","journal-title":"Qual Life Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01124-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01124-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01124-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T07:53:09Z","timestamp":1700293989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01124-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01124-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"1 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by the Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation, Japan. All decisions concerning the planning, implementation, and publication of this study were made by the executive committee of this study. The corporate and individual sponsors of this study are listed on the CSPOR website ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HI has a potential conflict of interest with Chugai Pharmaceutical Co. Ltd, Pfizer Inc, and Sanofi S.A. MT has a potential conflict of interest with Chugai Pharmaceutical Co. Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our data are available only on the CSPOR data center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was one of the secondary endpoints in the RESPECT trial, which was a randomized, open-label clinical trial. The study protocol of the RESPECT trial conformed with the guidelines of the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of Japan\u2019s Ministry of Health, Labor, and Welfare. It was approved by an independent ethics committee for each participating site. All participants provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"We used data from the RESPECT trial, which obtained informed consent from the respondents under those conditions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YT and TS were involved in the conception and design of the study. All authors contributed to the analysis or interpretation of data for this work, contributed in drafting or revising it critically for important intellectual content, and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}